Blinatumomab

Burkitt Lymphoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 95/ 100

Competitive context

73 Active assets in the Burkitt Lymphoma cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Fred Hutchinson Cancer Center	Phase 4	BBB
VINCRISTINE SULFATE AIDS Malignancy Consortium	Phase 2	BBB
VINDESINE PETHEMA Foundation	Phase 4	BBB
Cyclophosphamide AIDS Malignancy Consortium	Phase 4	BBB
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2	BBB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant

BBB

Indicative ·

72 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BBB

Indicative ·

72 / 100

Precursor B-Cell Acute Lymphoblastic LeukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.